T-DM1 Offers Similar PFS, More Tolerable in Advanced HER2-Positive Breast Cancer

The antibody-drug conjugate trastuzumab emtansine (T-DM1) showed non-inferior—but not superior—efficacy to trastuzumab plus a taxane in women with advanced HER2-positive breast cancer, according to a phase III trial. T-DM1 alone and in combination with pertuzumab showed similar results.

click me